Literature DB >> 22416902

Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis: a randomized controlled trial.

U K Misra1, J Kalita, S Chandra, B Kumar, V Bansal.   

Abstract

BACKGROUND: There is no randomized controlled trial (RCT) evaluating the efficacy and safety of low molecular weight heparin (LMWH) compared to unfractionated heparin (UFH) in cerebral venous sinus thrombosis (CVST). In this RCT, we have evaluated the efficacy and safety of LMWH versus UFH in CVST.
METHODS: Consecutive patients with CVST diagnosed on the basis of MR venography (MRV) who was free of bleeding diathesis, malignancy, hepatic or renal failure were prospectively enrolled. History, clinical findings and risk factors were evaluated. MRI and MRV findings were recorded. The patients were randomized to LMWH and UFH groups for 14 days followed by oral anticoagulant. The hospital mortality and 3 months outcome as assessed by Barthel index (BI) score were noted.
RESULTS: 32 patients received UFH and 34 received LMWH. The baseline demographic, clinical and radiological parameters were similar in both the groups. Six patients died and all were in UFH group (P = 0.01). At 3 months, insignificantly higher number of patients recovered completely in LMWH compared to UFH group (30 vs. 20). There was no serious side effect needing withdrawal of drugs except one was withdrawn from UFH because of heparin-induced thrombosis.
CONCLUSION: Low molecular weight heparin resulted in significantly lower hospital mortality in CVST compared to UFH.
© 2012 The Author(s) European Journal of Neurology © 2012 EFNS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22416902     DOI: 10.1111/j.1468-1331.2012.03690.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  34 in total

1.  [Diagnostic and treatment recommendations from the FACME ad-hoc expert working group on the management of cerebral venous sinus thrombosis associated with COVID-19 vaccination].

Authors: 
Journal:  Neurologia       Date:  2021-05-06       Impact factor: 3.109

Review 2.  Cerebral venous thrombosis.

Authors:  Suzanne M Silvis; Diana Aguiar de Sousa; José M Ferro; Jonathan M Coutinho
Journal:  Nat Rev Neurol       Date:  2017-08-18       Impact factor: 42.937

Review 3.  Diagnosis and management of cerebral venous thrombosis.

Authors:  Roya Behrouzi; Martin Punter
Journal:  Clin Med (Lond)       Date:  2018-02       Impact factor: 2.659

4.  [Diagnostic and treatment standards for cerebral sinus venous thrombosis : Results of an online survey of German stroke units].

Authors:  C Geisbüsch; P A Ringleb; O Busse; G F Hamann; S Nagel
Journal:  Nervenarzt       Date:  2017-10       Impact factor: 1.214

5.  Do the Risk Factors Determine the Severity and Outcome of Cerebral Venous Sinus Thrombosis?

Authors:  Jayantee Kalita; Usha K Misra; Rajesh K Singh
Journal:  Transl Stroke Res       Date:  2018-01-10       Impact factor: 6.829

6.  Rare presentation of iron deficiency anaemia with cerebral venous sinus thrombosis in a middle-aged woman.

Authors:  Amna Bibi; Chathuri Liyanapthirana; Sajjad Khan
Journal:  BMJ Case Rep       Date:  2019-01-17

Review 7.  Antithrombotic Therapy to Prevent Recurrent Strokes in Ischemic Cerebrovascular Disease: JACC Scientific Expert Panel.

Authors:  Victor J Del Brutto; Seemant Chaturvedi; Hans-Christoph Diener; Jose G Romano; Ralph L Sacco
Journal:  J Am Coll Cardiol       Date:  2019-08-13       Impact factor: 24.094

8.  Anticoagulation for noncardiac indications in neurologic patients: comparative use of non-vitamin k oral anticoagulants, low-molecular-weight heparins, and warfarin.

Authors:  Ariela L Marshall; Jean-Marie Connors
Journal:  Curr Treat Options Neurol       Date:  2014-09       Impact factor: 3.598

Review 9.  Diagnosis and treatment of cerebral venous and sinus thrombosis.

Authors:  Christian Weimar
Journal:  Curr Neurol Neurosci Rep       Date:  2014-01       Impact factor: 5.081

Review 10.  Cerebral venous sinus thrombosis: update on diagnosis and management.

Authors:  José M Ferro; Patrícia Canhão
Journal:  Curr Cardiol Rep       Date:  2014-09       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.